SPOTLIGHT REVIEW ARTICLE
ARTICLES IN THREE SENTENCES
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment
Few data are available for patients with multiple myeloma and renal impairment (RI) treated with chimeric antigen receptor (CAR) T-cell therapy. Sidana and colleagues analyzed outcome of treatment with idecabtagene vicleucel (ide-cel) in patients with RI compared with patients without RI. They demonstrated that ide-cel is feasible in patients with RI, with a comparable safety and efficacy profile as in patients without RI.
T-cell engaging bispecific antibody (T-BsAb)-based immunotherapy has produced impressive clinical responses in patients with relapsed/refractory B-cell malignancies, although treatment failure and relapse remain major clinical challenges. Casey and colleagues studied the functional impact of regulatory T (Treg) cells on anti-tumor immunity elicited by T-BsAb therapy. They demonstrated that therapy-induced activation of Treg cells critically regulates anti-tumor immunity elicited by T-BsAb therapy, with important implications for improving the efficacy of such treatment.
Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study
As cancer treatments improve and patients live longer, it has become more important to evaluate the impact of new treatments on patients’ health-related quality of life (HRQOL). Lisocabtagene maraleucel (liso-cel), an autologous, CD19-directed, 4-1BB chimeric antigen receptor (CAR) T-cell product, showed high efficacy and a good safety profile as second-line treatment in patients with relapsed or refractory (R/R) large B-cell lymphoma. Gordon and colleagues report results of the HRQOL of the phase II PILOT study showing that HRQOL was maintained or improved in patients with R/R large B-cell lymphoma treated with liso-cel.
Megakaryocytes (MK) generate platelets by remodeling their cytoplasm into long proplatelet extensions, but within this process the role of the actin cytoskeleton is not well defined. Becker and colleagues identified Cdc42 and its downstream effectors, septins, as critical regulators of intracellular actin dynamics during proplatelet formation in MK. They provide a novel insight into how a third cytoskeletal component, the septin cytoskeleton, regulates actin dynamics, thus contributing to effective proplatelet formation.
TAKE ADVANTAGE FROM HAEMATOLOGICA